Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030

Khalid Alswat, Abdulrahman A. Aljumah, Faisal M. Sanai, Faisal Abaalkhail, Mohamed Alghamdi, Waleed K. Al Hamoudi, Abdullah Al Khathlan, Huda Al Quraishi, Ahmed Al Rifai, Mohammed A l Za'abi, Mohamed A. Babatin, Chris Estes, Almoutaz Hashim, Homie Razavi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aim: Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver disease burden in the coming years in Saudi Arabia and United Arab Emirates (UAE). Materials and Methods: Models were used to estimate NAFLD and NASH disease progression, primarily based on changes in adult prevalence rates of adult obesity and DM. The published estimates and expert interviews were used to build and validate the model projections. Results: In both countries, the prevalence of NAFLD increased through 2030 parallel to projected increases in the prevalence of obesity and DM. By 2030, there were an estimated 12,534,000 NAFLD cases in Saudi Arabia and 372,000 cases in UAE. Increases in NASH cases were relatively greater than the NAFLD cases due to aging of the population and disease progression. Likewise, prevalent cases of compensated cirrhosis and advanced liver disease are projected to at least double by 2030, while annual incident liver deaths increase in both countries to 4800 deaths in Saudi Arabia and 140 deaths in UAE. Conclusions: Continued high rates of adult obesity and DM, in combination with aging populations, suggest that advanced liver disease and mortality attributable to NAFLD/NASH will increase across both countries. Reducing the growth of the NAFLD population, along with potential therapeutic options, will be needed to reduce liver disease burden.

Original languageEnglish
Pages (from-to)211-219
Number of pages9
JournalSaudi Journal of Gastroenterology
Volume24
Issue number4
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

United Arab Emirates
Saudi Arabia
Liver Diseases
Obesity
Diabetes Mellitus
Disease Progression
Non-alcoholic Fatty Liver Disease
Population
Type 2 Diabetes Mellitus
Fibrosis

Keywords

  • Burden of disease
  • cardiovascular disease
  • cirrhosis
  • decompensated cirrhosis
  • healthcare resource utilization
  • hepatocellular carcinoma
  • metabolic syndrome
  • nonalcoholic fatty liver
  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis
  • obesity
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Alswat, K., Aljumah, A. A., Sanai, F. M., Abaalkhail, F., Alghamdi, M., Al Hamoudi, W. K., ... Razavi, H. (2018). Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030. Saudi Journal of Gastroenterology, 24(4), 211-219. https://doi.org/10.4103/sjg.SJG_122_18

Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030. / Alswat, Khalid; Aljumah, Abdulrahman A.; Sanai, Faisal M.; Abaalkhail, Faisal; Alghamdi, Mohamed; Al Hamoudi, Waleed K.; Al Khathlan, Abdullah; Al Quraishi, Huda; Al Rifai, Ahmed; A l Za'abi, Mohammed; Babatin, Mohamed A.; Estes, Chris; Hashim, Almoutaz; Razavi, Homie.

In: Saudi Journal of Gastroenterology, Vol. 24, No. 4, 01.07.2018, p. 211-219.

Research output: Contribution to journalArticle

Alswat, K, Aljumah, AA, Sanai, FM, Abaalkhail, F, Alghamdi, M, Al Hamoudi, WK, Al Khathlan, A, Al Quraishi, H, Al Rifai, A, A l Za'abi, M, Babatin, MA, Estes, C, Hashim, A & Razavi, H 2018, 'Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030', Saudi Journal of Gastroenterology, vol. 24, no. 4, pp. 211-219. https://doi.org/10.4103/sjg.SJG_122_18
Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK et al. Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030. Saudi Journal of Gastroenterology. 2018 Jul 1;24(4):211-219. https://doi.org/10.4103/sjg.SJG_122_18
Alswat, Khalid ; Aljumah, Abdulrahman A. ; Sanai, Faisal M. ; Abaalkhail, Faisal ; Alghamdi, Mohamed ; Al Hamoudi, Waleed K. ; Al Khathlan, Abdullah ; Al Quraishi, Huda ; Al Rifai, Ahmed ; A l Za'abi, Mohammed ; Babatin, Mohamed A. ; Estes, Chris ; Hashim, Almoutaz ; Razavi, Homie. / Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030. In: Saudi Journal of Gastroenterology. 2018 ; Vol. 24, No. 4. pp. 211-219.
@article{9a2f28422483412f84850e329e52e05c,
title = "Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030",
abstract = "Background/Aim: Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver disease burden in the coming years in Saudi Arabia and United Arab Emirates (UAE). Materials and Methods: Models were used to estimate NAFLD and NASH disease progression, primarily based on changes in adult prevalence rates of adult obesity and DM. The published estimates and expert interviews were used to build and validate the model projections. Results: In both countries, the prevalence of NAFLD increased through 2030 parallel to projected increases in the prevalence of obesity and DM. By 2030, there were an estimated 12,534,000 NAFLD cases in Saudi Arabia and 372,000 cases in UAE. Increases in NASH cases were relatively greater than the NAFLD cases due to aging of the population and disease progression. Likewise, prevalent cases of compensated cirrhosis and advanced liver disease are projected to at least double by 2030, while annual incident liver deaths increase in both countries to 4800 deaths in Saudi Arabia and 140 deaths in UAE. Conclusions: Continued high rates of adult obesity and DM, in combination with aging populations, suggest that advanced liver disease and mortality attributable to NAFLD/NASH will increase across both countries. Reducing the growth of the NAFLD population, along with potential therapeutic options, will be needed to reduce liver disease burden.",
keywords = "Burden of disease, cardiovascular disease, cirrhosis, decompensated cirrhosis, healthcare resource utilization, hepatocellular carcinoma, metabolic syndrome, nonalcoholic fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, obesity, type 2 diabetes mellitus",
author = "Khalid Alswat and Aljumah, {Abdulrahman A.} and Sanai, {Faisal M.} and Faisal Abaalkhail and Mohamed Alghamdi and {Al Hamoudi}, {Waleed K.} and {Al Khathlan}, Abdullah and {Al Quraishi}, Huda and {Al Rifai}, Ahmed and {A l Za'abi}, Mohammed and Babatin, {Mohamed A.} and Chris Estes and Almoutaz Hashim and Homie Razavi",
year = "2018",
month = "7",
day = "1",
doi = "10.4103/sjg.SJG_122_18",
language = "English",
volume = "24",
pages = "211--219",
journal = "Saudi Journal of Gastroenterology",
issn = "1319-3767",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030

AU - Alswat, Khalid

AU - Aljumah, Abdulrahman A.

AU - Sanai, Faisal M.

AU - Abaalkhail, Faisal

AU - Alghamdi, Mohamed

AU - Al Hamoudi, Waleed K.

AU - Al Khathlan, Abdullah

AU - Al Quraishi, Huda

AU - Al Rifai, Ahmed

AU - A l Za'abi, Mohammed

AU - Babatin, Mohamed A.

AU - Estes, Chris

AU - Hashim, Almoutaz

AU - Razavi, Homie

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background/Aim: Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver disease burden in the coming years in Saudi Arabia and United Arab Emirates (UAE). Materials and Methods: Models were used to estimate NAFLD and NASH disease progression, primarily based on changes in adult prevalence rates of adult obesity and DM. The published estimates and expert interviews were used to build and validate the model projections. Results: In both countries, the prevalence of NAFLD increased through 2030 parallel to projected increases in the prevalence of obesity and DM. By 2030, there were an estimated 12,534,000 NAFLD cases in Saudi Arabia and 372,000 cases in UAE. Increases in NASH cases were relatively greater than the NAFLD cases due to aging of the population and disease progression. Likewise, prevalent cases of compensated cirrhosis and advanced liver disease are projected to at least double by 2030, while annual incident liver deaths increase in both countries to 4800 deaths in Saudi Arabia and 140 deaths in UAE. Conclusions: Continued high rates of adult obesity and DM, in combination with aging populations, suggest that advanced liver disease and mortality attributable to NAFLD/NASH will increase across both countries. Reducing the growth of the NAFLD population, along with potential therapeutic options, will be needed to reduce liver disease burden.

AB - Background/Aim: Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver disease burden in the coming years in Saudi Arabia and United Arab Emirates (UAE). Materials and Methods: Models were used to estimate NAFLD and NASH disease progression, primarily based on changes in adult prevalence rates of adult obesity and DM. The published estimates and expert interviews were used to build and validate the model projections. Results: In both countries, the prevalence of NAFLD increased through 2030 parallel to projected increases in the prevalence of obesity and DM. By 2030, there were an estimated 12,534,000 NAFLD cases in Saudi Arabia and 372,000 cases in UAE. Increases in NASH cases were relatively greater than the NAFLD cases due to aging of the population and disease progression. Likewise, prevalent cases of compensated cirrhosis and advanced liver disease are projected to at least double by 2030, while annual incident liver deaths increase in both countries to 4800 deaths in Saudi Arabia and 140 deaths in UAE. Conclusions: Continued high rates of adult obesity and DM, in combination with aging populations, suggest that advanced liver disease and mortality attributable to NAFLD/NASH will increase across both countries. Reducing the growth of the NAFLD population, along with potential therapeutic options, will be needed to reduce liver disease burden.

KW - Burden of disease

KW - cardiovascular disease

KW - cirrhosis

KW - decompensated cirrhosis

KW - healthcare resource utilization

KW - hepatocellular carcinoma

KW - metabolic syndrome

KW - nonalcoholic fatty liver

KW - nonalcoholic fatty liver disease

KW - nonalcoholic steatohepatitis

KW - obesity

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85051179023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051179023&partnerID=8YFLogxK

U2 - 10.4103/sjg.SJG_122_18

DO - 10.4103/sjg.SJG_122_18

M3 - Article

VL - 24

SP - 211

EP - 219

JO - Saudi Journal of Gastroenterology

JF - Saudi Journal of Gastroenterology

SN - 1319-3767

IS - 4

ER -